DOPAL is transmissible to and oligomerizes alpha-synuclein in human glial cells

Autonomic Neuroscience: Basic and Clinical

Volumn 194, Issue , 2016, Pages 46-51

  Jinsmaa, Yunden ^a   Sullivan, Patricia ^a   Sharabi, Yehonatan ^b   Goldstein, David S ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

DOPAL; Glial cytoplasmic inclusions; Multiple system atrophy; Parkinson's disease; Synuclein

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; ALPHA SYNUCLEIN; LEVODOPA; 3,4-DIHYDROXYPHENYLACETALDEHYDE; CATECHOLAMINE; PROTEIN AGGREGATE;

ARTICLE; CATECHOLAMINE METABOLISM; CONTROLLED STUDY; GLIA CELL; HUMAN; HUMAN CELL; OLIGOMERIZATION; PC12 CELL LINE; PRIORITY JOURNAL; PROTEIN TRANSPORT; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; CELL FRACTIONATION; CELL LINE; DOSE RESPONSE; DRUG EFFECTS; GENETICS; GLIA; GLIOBLASTOMA; METABOLISM; MUTATION; PATHOLOGY; RAT; TIME FACTOR;

3,4-DIHYDROXYPHENYLACETIC ACID; ALPHA-SYNUCLEIN; ANIMALS; CATECHOLAMINES; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GLIOBLASTOMA; HUMANS; MUTATION; NEUROGLIA; PC12 CELLS; PROTEIN AGGREGATES; RATS; SUBCELLULAR FRACTIONS; TIME FACTORS;

EID: 84983184214     PISSN: 15660702     EISSN: 18727484     Source Type: Journal    
DOI: 10.1016/j.autneu.2015.12.008     Document Type: Article

References (20)

1. Anderson D.G., Mariappan S.V., Buettner G.R., Doorn J.A. Oxidation of 3,4-dihydroxyphenylacetaldehyde, a toxic dopaminergic metabolite, to a semiquinone radical and an ortho-quinone. J. Biol. Chem. 2011, 286:26978-26986.
2. Buntinx M., Vanderlocht J., Hellings N., Vandenabeele F., Lambrichts I., Raus J., Ameloot M., Stinissen P., Steels P. Characterization of three human oligodendroglial cell lines as a model to study oligodendrocyte injury: morphology and oligodendrocyte-specific gene expression. J. Neurocytol. 2003, 32:25-38.
3. Burke W.J., Kumar V.B., Pandey N., Panneton W.M., Gan Q., Franko M.W., O'Dell M., Li S.W., Pan Y., Chung H.D., Galvin J.E. Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. Acta Neuropathol. 2008, 115:193-203.
4. Dickson D.W., Lin W., Liu W.K., Yen S.H. Multiple system atrophy: a sporadic synucleinopathy. Brain Pathol. 1999, 9:721-732.
5. el-Agnaf O.M., Irvine G.B. Aggregation and neurotoxicity of alpha-synuclein and related peptides. Biochem. Soc. Trans. 2002, 30:559-565.
6. Goldstein D.S., Sullivan P., Cooney A., Jinsmaa Y., Sullivan R., Gross D.J., Holmes C., Kopin I.J., Sharabi Y. Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson disease. J. Neurochem. 2012, 123:932-943.
7. Goldstein D.S., Sullivan P., Holmes C., Kopin I.J., Sharabi Y., Mash D.C. Decreased vesicular storage and aldehyde dehydrogenase activity in multiple system atrophy. Parkinsonism Relat. Disord. 2015.
8. Hoyer W., Cherny D., Subramaniam V. Rapid self-assembly of alpha-synuclein observed by in situ atomic force microscopy. J. Mol. Biol. 2004, 340:127-139.
9. Miller D.W., Johnson J.M., Solano S.M., Hollingsworth Z.R., Standaert D.G., Young A.B. Absence of alpha-synuclein mRNA expression in normal and multiple system atrophy oligodendroglia. J. Neural Transm. 2005, 112:1613-1624.
10. Mukaetova-Ladinska E.B., McKeith I.G. Pathophysiology of synuclein aggregation in Lewy body disease. Mech. Ageing 2006, 127:188-202.
11. Panneton W.M., Kumar V.B., Gan Q., Burke W.J., Galvin J.E. The neurotoxicity of DOPAL: behavioral and stereological evidence for its role in Parkinson disease pathogenesis. PLoS One 2010, 5.
12. Papp M.I., Kahn J.E., Lantos P.L. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J. Neurol. Sci. 1989, 94:79-100.
13. Pasanen P., Myllykangas L., Siitonen M., Raunio A., Kaakkola S., Lyytinen J., Tienari P.J., Pöyhönen M., Paetau A. A novel α-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson's disease-type pathology. Neurobiol. Aging 2014, 35. (2180.e2181-2185).
14. Prusiner S.B., Woerman A.L., Mordes D.A., Watts J.C., Rampersaud R., Berry D.B., Patel S., Oehler A., Lowe J.K., Kravitz S.N., Geschwind D.H., Glidden D.V., Halliday G.M., Middleton L.T., Gentleman S.M., Grinberg L.T., Giles K. Evidence for alpha-synuclein prions causing multiple system atrophy in humans with parkinsonism. Proc. Natl. Acad. Sci. U. S. A. 2015, 112:E5308-E5317.
15. Pukass K., Richter-Landsberg C. Oxidative stress promotes uptake, accumulation, and oligomerization of extracellular alpha-synuclein in oligodendrocytes. J. Mol. Neurosci. 2014, 52:339-352.
16. Rees J.N., Florang V.R., Eckert L.L., Doorn J.A. Protein reactivity of 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite, is dependent on both the aldehyde and the catechol. Chem. Res. Toxicol. 2009, 22:1256-1263.
17. Reyes J.F., Rey N.L., Bousset L., Melki R., Brundin P., Angot E. Alpha-synuclein transfers from neurons to oligodendrocytes. Glia 2014, 62:387-398.
18. Scholz S.W., Houlden H., Schulte C., Sharma M., Li A., Berg D., Melchers A., Paudel R., Gibbs J.R., Simon-Sanchez J., Paisan-Ruiz C., Bras J., Ding J., Chen H., Traynor B.J., Arepalli S., Zonozi R.R., Revesz T., Holton J., Wood N., Lees A., Oertel W., Wullner U., Goldwurm S., Pellecchia M.T., Illig T., Riess O., Fernandez H.H., Rodriguez R.L., Okun M.S., Poewe W., Wenning G.K., Hardy J.A., Singleton A.B., DEL Sorbo F., Schneider S., Bhatia K.P., Gasser T. SNCA variants are associated with increased risk for multiple system atrophy. Ann. Neurol. 2009, 65:610-614.
19. Tu P.H., Galvin J.E., Baba M., Giasson B., Tomita T., Leight S., Nakajo S., Iwatsubo T., Trojanowski J.Q., Lee V.M. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann. Neurol. 1998, 44:415-422.
20. Winner B., Jappelli R., Maji S.K., Desplats P.A., Boyer L., Aigner S., Hetzer C., Loher T., Vilar M., Campioni S., Tzitzilonis C., Soragni A., Jessberger S., Mira H., Consiglio A., Pham E., Masliah E., Gage F.H., Riek R. In vivo demonstration that alpha-synuclein oligomers are toxic. Proc. Natl. Acad. Sci. U. S. A. 2011.